NCT06291467

Plasma Beta-endorphin Levels and Suicidal Behavior

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 104 (estimated)
• Sponsor: University Hospital, Montpellier · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

It is an interventional research, monocentric, which involves only minimal risks and constraints. Psychological pain is closely associated with suicidal ideation (SI) and suicidal behavior, regardless of the severity of the depression. The psychological pain being regulated by the opioidergic system, it seems that a dysfunction of this system exists in suicidal attempters. The aim of this study is to explore the association between levels of β-endorphin and suicidal behavior. The research team will measure plasma levels of β-endorphin in patients hospitalized for suicide attempt (SA) within 72 hours and compare them to those of patients hospitalized for current major depressive episode (EDC) without any lifetime history of SA. In order to follow the kinetics of β endorphin levels, The research team will carry out two measurements: at inclusion and on day 7 (+/- 2 days) of inclusion. The main objective is to compare plasma β-endorphin levels in patients hospitalized following a recent SA (≤72 hours) and in patients hospitalized for an EDC without lifetime history of SA.

Detailed description

104 participants will be enrolled, divided into 2 groups: group 1: 52 Suicide attempters, currently hospitalized patients for a suicide attempt within the 72 last hours group 2: 50 Affective controls, currently hospitalized patients for current major depressive episode according to the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria and without any lifetime history of suicide attempt; The protocol includes two visits.The first visit is the inclusion visit carried out at the beginning of patient hospitalization, within 72 hours following suicide attempt (SA) for group 1 (suicide attempters) and within 72 hours following the admission to hospital for group 2 (affective controls). The second visit takes place at the end of hospitalisation, on Day 7 +/- 2 days, after SA for group 1 and after admission to hospital for group 2 . At each visit, a clinical assessment will be performed to characterise psychopathology and suicidal characteristics. Blood samples will be obtained in order to measure beta-β-endorphin levels.

Conditions

• Suicide
• Depression
• Beta Endorphin

Interventions

Type	Name	Description
BIOLOGICAL	Blood samples	Blood samples will be collected at both visit between 8:30 a.m. and 9:30 a.m. and fasting from midnight.
OTHER	questionnaires	Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits. Hetero-questionnaires will be administrated during a clinical interview conducted by a psychiatrist or psychologist at the inclusion. * MINI 7.0 Mini-International Neuropsychiatric Interview : * MADRS (Montgomery Asberg Depression Scale) * C-SSRS (Columbia-Suicide Severity Rating Scale) * FAST (Functioning Assessment Short Test) Self-administered questionnaire will be completed by the participant at the inclusion and at the end of hospitalisation (D7+/- 2 days) : * STAI-Y (State-Trait Anxiety Inventory ) * PPP-VAS (Visual Analog Scale to measure Psychological and Physical Pain) * SHAPS (Snaith-Hamilton-Pleasure Scale ) * CTQ (Childhood Trauma Questionnaire) * ESUL : Echelle de solitude de l'université de Laval * BIS-11 : (Barratt Impulsiveness Scale) * QIDS (Quick Inventory of Depressive Symptomatology)

Timeline

• Start date: 2024-03-01
• Primary completion: 2026-03-01
• Completion: 2026-03-01
• First posted: 2024-03-04
• Last updated: 2024-03-04

Locations

1 site across 1 country: France